TRxADE HEALTH, Inc. (MEDS)
- Previous Close
5.91 - Open
5.80 - Bid --
- Ask --
- Day's Range
5.65 - 5.92 - 52 Week Range
3.69 - 44.56 - Volume
5,076 - Avg. Volume
443,109 - Market Cap (intraday)
7.997M - Beta (5Y Monthly) 2.04
- PE Ratio (TTM)
-- - EPS (TTM)
-17.96 - Earnings Date May 15, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 25, 2024
- 1y Target Est
--
TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida.
www.trxadehealth.com8
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MEDS
Performance Overview: MEDS
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDS
Valuation Measures
Market Cap
8.33M
Enterprise Value
15.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.70
Price/Book (mrq)
15.35
Enterprise Value/Revenue
1.74
Enterprise Value/EBITDA
-5.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-215.71%
Return on Assets (ttm)
-55.90%
Return on Equity (ttm)
-3,099.92%
Revenue (ttm)
8.27M
Net Income Avi to Common (ttm)
-13.72M
Diluted EPS (ttm)
-17.96
Balance Sheet and Cash Flow
Total Cash (mrq)
151.91k
Total Debt/Equity (mrq)
1,309.83%
Levered Free Cash Flow (ttm)
-2.19M
Research Analysis: MEDS
Company Insights: MEDS
MEDS does not have Company Insights